Pathnostics has received approval from the New York State Department of Health (NYSDOH) in the US for its Guidance urinary tract infection (UTI) test.
Approved through the NYSDOH Clinical Laboratory Evaluation Programme, the test enables urologists and urogynecologists to quickly diagnose and accurately treat recurrent, complicated and persistent UTIs.
It is said to be the only NYSDOH-approved advanced UTI test that leverages advanced molecular technology to detect organisms and resistance genes combined with pooled antibiotic susceptibility results.
Compared with standard urine culture testing, which can take up to five days to generate results, the Guidance UTI test offers results within a day after receiving samples in the lab.
It provides the highest level of diagnostic specificity and sensitivity against standard testing, including specific uropathogens detection, even in the presence of several organisms.
Furthermore, Guidance UTI significantly lowers emergency and urgent care visits and patient hospitalisations and empiric therapy rates.
Pathnostics CEO David Pauluzzi said: “We are thrilled that our Guidance UTI test has been approved by an organisation renowned for its expertise, high standards and stringent process for validating clinical lab tests.
“Earning this approval is a testament to the Guidance UTI test and its impact in addressing a complex health challenge.”
Pathnostics, a precision diagnostic testing and development company, offers solutions for infectious disease and cancer diagnostics. Its Guidance solutions platform utilises patented technology for pooled antibiotic susceptibility testing.
